OncoMatch/Clinical Trials/NCT06427941
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Is NCT06427941 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including BGB-B2033 and Tislelizumab for metastatic hepatocellular carcinoma.
Treatment: BGB-B2033 · Tislelizumab · Bevacizumab — This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033 administered as monotherapy and in combination with tislelizumab, with or without bevacizumab. The study will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP)-producing gastric cancer (GC), extragonadal yolk sac tumors/non-dysgerminomas, or glypican-3 (GPC3)-positive squamous non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Hepatocellular Carcinoma
Gastric Cancer
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: AFP overexpression (> 20 ng/mL in blood or tumor tissue positive for AFP by IHC)
AFP > 20 ng/mL in blood or tumor tissue positive for AFP by a validated immunohistochemistry (IHC) assay
Required: GPC3 overexpression (GPC3-positive)
Glypican-3 (GPC3)-positive squamous non-small cell lung cancer (NSCLC)
Disease stage
Required: Stage BCLC STAGE B, BCLC STAGE C, III, IV (BCLC)
unresectable, locally advanced, or metastatic tumor types
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: checkpoint inhibitor
prior exposure to a checkpoint inhibitor (CPI)
Cannot have received: GPC3-targeted therapy
Prior therapy directed against glypican-3 (GPC3)
Cannot have received: CD137-targeted therapy
Prior therapy directed against...the T-cell costimulatory receptor 4-1BB (CD137)
Lab requirements
Blood counts
Adequate organ function as defined in the protocol
Kidney function
Adequate organ function as defined in the protocol
Liver function
Adequate organ function as defined in the protocol
Adequate organ function as defined in the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center Mskcc · New York, New York
- Upmc Hillman Cancer Center(Univ of Pittsburgh) · Pittsburgh, Pennsylvania
- Scri Oncology Partners · Nashville, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06427941 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior GPC3-targeted therapy, CD137-targeted therapy disqualifies patients from enrollment.
Does this trial require AFP?
Yes, AFP overexpression is a required biomarker for enrollment.
Does this trial require GPC3?
Yes, GPC3 overexpression is a required biomarker for enrollment.
What disease stage is eligible?
Stage BCLC STAGE B or BCLC STAGE C or III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages